

## EDITORIAL COMMENT

This current study confirms that zoledronate exerts a favorable effect on skeletal-related events in patients with renal cell carcinoma (RCC) and bone metastases. A multicenter study to determine whether zoledronate also delays the development of bone metastases is being conducted in hormone-sensitive prostate cancer patients.<sup>1</sup> Denosumab, a RANK ligand inhibitor, has already been shown to delay time to first bone metastasis in men with castration-resistant prostate cancer.<sup>2</sup>

It is of interest that combining a bone-targeted agent, such as zoledronate, with antitumor therapy may improve survival of patients with cancer.<sup>3,4</sup> These findings suggest that zoledronate has additional mechanisms of action that enhance the antitumor effects of conventional therapies. However, in our anecdotal experience, potentially severe acute renal failure can occur in RCC patients receiving combined therapy with zoledronate and mTOR inhibitors such as everolimus or temsirolimus. It is prudent to carefully monitor these patients for serum creatinine elevations and electrolyte abnormalities during treatment.

Shi-Ming Tu, MD  
Associate Professor

Adrienne H. Chen, PharmD, BCPS  
Clinical Pharmacist

Department of Genitourinary Medical Oncology  
UT MD Anderson Cancer Center  
Houston, Texas USA

## References

1. Wirth M, Tammela T, Debruyne F, Tubaro A. Effectiveness of zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A randomised, open label, multicenter study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). A report of the ZEUS study [abstract 184]. Presented at: 2008 Genitourinary Cancer Symposium; February 14-16, 2008; San Francisco, CA.
2. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomized, placebo-controlled trial. *Lancet* 2012;379(9810):39-46.
3. Morgan GJ, Davies FE, Gregory WM et al. First-line treatment using zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. *Lancet* 2010;376(9757):1989-1999.
4. Gnant M, Mlineritsch B, Stoeger H et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-months follow-up from the ABCSG-12 randomised trial. *Lancet Oncol* 2011;12(7):631-641.